Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 8/20 | 0.58 |
| ▸ | MAPK3 | P27361 | 4/20 | 0.56 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.55 |
| ▸ | FLT3 | P36888 | 6/20 | 0.51 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.49 |
| ▸ | TTK | P33981 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6426385 | 0.84 | HDAC3 (0.41) | MAPK1MAPK3CSNK1DMAPK8 | |
| SCHEMBL13927652 | 0.82 | MTNR1A (0.43) | MAPK1MAPK3CSNK1DMAPK8 | |
| SCHEMBL2868363 | 0.82 | ITK (0.58) | MAPK1MAPK3CSNK1DFLT3TTK | |
| SCHEMBL13198214 | 0.81 | MAPK1 (0.55) | MAPK1MAPK3CSNK1DFLT3MAPK8 | |
| SCHEMBL2868308 | 0.81 | CDK4 (0.60) | — | |
| SCHEMBL2861069 | 0.80 | ALPL (0.54) | MAPK1MAPK3CSNK1DFLT3 | |
| SCHEMBL4327031 | 0.80 | MTNR1A (0.41) | MAPK1 | |
| SCHEMBL13811895 | 0.79 | FLT3 (0.58) | MAPK1MAPK3CSNK1DFLT3 | |
| SCHEMBL2855850 | 0.79 | MAP2K4 (0.59) | MAPK1MAPK3CSNK1D | |
| SCHEMBL4343191 | 0.78 | MAPK1 (0.52) | MAPK1MAPK3CSNK1DFLT3TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-7776890-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-1380576-B1 | 1H-INDAZOLE COMPOUNDS INHIBITING JNK | EISAI R&D MAN CO LTD (JP) | 2009-11-25 | — | — | EP | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-20090203691-A1 | Novel 1H-indazole compounds | OINUMA HITOSHI | 2009-08-13 | — | — | US | disclosed |
| US-7541376-B2 | 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-02 | — | — | US | disclosed |
| US-6982274-B2 | 1H-indazole compound | EISAI CO., LTD. (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20050282880-A1 | Novel 1H-indazole compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20040127538-A1 | Novel 1h-indazole compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203691-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAPK1 1/4885MAPK3 2/4885CSNK1D 134/4885 |
| US-20040127538-A1 | Novel 1h-indazole compound | MAPK1, MAPK14, MAPK3 | MAPK1 1/4885MAPK3 3/4885CSNK1D 90/4885 |
| US-20050282880-A1 | Novel 1H-indazole compounds | MAPK1, MAPK3, MAPK13 | MAPK1 1/4885MAPK3 2/4885CSNK1D 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.